The development and testing of potential HIV cure therapeutics would be greatly expedited by a robust set of biomarkers predicting their clinical effectiveness. Biomarkers that can serve as surrogate endpoints remain unidentified. Such biomarkers will: 1) accelerate progress in the HIV cure arena much like plasma viral load testing propelled antiviral drug development; 2) afford patients participating in analytical treatment interruption (ATI) trials a higher degree of clinical protection by both reducing the number of trials; 3) provide biological clues into the molecular and biochemical pathways that control the latent reservoir; and 4) serve as a magnet for attracting Biotech and Pharma to more vigorously engage in HIV cure research. The BioMark program project team (Warner Greene, Gilad Doitsh, Garry Nolan, Katie Pollard, Satish Pillai, Nadia Roan, and Robert Siliciano) will search for strong biomarkers that accurately predict time to rebound following treatment interruption. Such biomarkers would be of great value for the cure field as they would allow clinicians to predict the period of time a patient can remain off ART without viral recrudescence. Blood cells and plasma from 125 HIV-infected volunteers participating in four different ATI trials obtained before ATI and at the time of viral rebound will be analyzed. These patients include 30 individuals treated during acute infection who are expected to exhibit slower rebound times. To identify both virus- and host-derived biomarkers, the team will 1) deploy an exciting ?first in class? digital droplet PCR assay that selectively detects and quantitates intact proviral DNAs (IPDA) in the reservoir??because it is this key small fraction of the total provirus population that contains the infectious proviruses mediating rebound, a low number of intact proviruses might emerge as a strong biomarker predicting a longer time to viral rebound; 2) utilize next-generation ultra-deep sequencing to profile cellular RNAs and miRNAs in CD4 T and other immune cells and in parallel to sequence DNA, RNA and miRNA circulating free in plasma (and in cerebrospinal fluid in a limited subset of subjects) or bound as cargoes in extracellular vesicles to identify predictors of time of viral rebound; 3) use 7 validated CyTOF panels comprising over >200 parameters to phenotypically study CD4 T cells and other immune cells under both resting and stimulated conditions to identify single-cell signatures of time to viral rebound; 4) assess changes in the titer and avidity of circulating anti-HIV antibodies or markers of lymphoid tissue inflammation (including products of pyroptosis) as indicators of the size of the expressed reservoir, which can serve as predictors of time to viral rebound. These studies will generate large bodies of high-dimensional data that will be compiled, curated, and analyzed in BioMark's Bioinformatics and Biostatistics Core. Several biostatistical approaches will be employed to identify these biomarkers and to perform the larger meta analysis (see Core description). In summary, BioMark proposes an innovative and comprehensive approach to fill a major gap in HIV cure research produced by a lack of key biomarkers predicting time to viral rebound after treatment interruption.

Public Health Relevance

This proposed research seeks to accelerate development of a cure for HIV-infected patients by identifying strong biomarkers that accurately determine whether a potential therapy is working or not. These biomarkers could propel HIV cure research like viral load testing facilitated antiviral drug development, plus these biomarkers would reduce the number therapeutic candidates for testing in costly, cumbersome, and potentially dangerous treatment interruption trials. Finally these studies are closely aligned with one of the top three strategic priorities for HIV research as defined by NIH's Office of AIDS Research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Mcdonald, David Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
J. David Gladstone Institutes
San Francisco
United States
Zip Code
Roan, Nadia R (2018) Resident T cells stand up to HIV. Sci Immunol 3: